PSMA PET/CT in Prostate Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: 20 November 2024 | Viewed by 930
Special Issue Editor
Special Issue Information
Dear Colleagues,
The introduction of PSMA PET/CT into clinical use has had a major impact on our management of prostate cancer. Its initial utilization was in the identification of disease in biochemical recurrence and, shortly after that, it became recognized as a superior tool in primary staging at diagnosis. The potential roles of PSMA PET/CT continue to expand and there is growing data to demonstrate its utility in the assessment of local disease. As such, there are emerging data that demonstrate its utility in diagnosis, active surveillance, and as a biomarker. This novel imaging has also paved the way for a therapeutic option and the exponential growth of interest in theranostics.
We are pleased to invite you to contribute manuscripts that provide emerging or mature data on how PSMA PET/CT has influenced prostate cancer management in your institution or systematically evaluate the research experience in specific applications of PSMA PET/CT. The aim of this Special Issue is to create a collection of papers that define the use of this novel form of imaging in urological clinical practice.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Diagnosis
- Staging
- Re-staging
- Predictive disease states
- Imaging biomarker
I look forward to receiving your contributions.
Dr. Henry Hyunshik Woo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- staging
- diagnosis
- radical prostatectomy
- biochemical recurrence
